• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经皮冠状动脉介入治疗患者中中重度冠状动脉钙化的长期预后。

Long-Term Prognosis of Moderate to Severe Coronary Artery Calcification in Patients Undergoing Percutaneous Coronary Intervention.

机构信息

Department of Cardiology, Fu Wai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College & Chinese Academy of Medical Sciences.

出版信息

Circ J. 2020 Dec 25;85(1):50-58. doi: 10.1253/circj.CJ-20-0761. Epub 2020 Dec 9.

DOI:10.1253/circj.CJ-20-0761
PMID:33298633
Abstract

BACKGROUND

Moderate/severe coronary artery calcification (CAC) predicts worse clinical outcomes in patients undergoing percutaneous coronary intervention (PCI). However, to date most studies have been modest in size and with limited follow-up. We aimed to assess the association between calcification severity and long-term clinical outcomes in a large cohort undergoing PCI.

METHODS AND RESULTS

In total, 10,068 consecutive patients who underwent PCI at Fuwai Hospital were enrolled in this prospective observational study. Patients were categorized as none/mild or moderate/severe CAC according to the severity of the target lesion by visual assessment of coronary angiography. Major adverse cardiovascular events (MACE), a composite event of death, myocardial infarction and revascularization, at 5 years were assessed. None/mild CAC was observed in 8,229 (81.7%) patients, and moderate/severe CAC was observed in 1,839 (18.3%) patients. Patients with moderate/severe CAC had a significantly higher rate of 5-year unplanned revascularization (15.2% vs. 13.2%, P=0.022) and MACE (20.7% vs. 17.9%, P=0.005). After propensity score matching, the moderate/severe CAC group still had a higher rate of 5-year unplanned revascularization (15.2% vs. 12.6%, P=0.019). Cox regression analysis using clinically significant variables revealed moderate/severe calcification was independently associated with higher risk of 2-year unplanned target vessel revascularization (hazard ratio (HR)=1.287, 95% confidence interval (CI): 1.036-1.600, P=0.023) and MACE (HR=1.242, 95% CI: 1.039-1.484, P=0.017), but not 5-year unplanned revascularization and MACE.

CONCLUSIONS

In patients undergoing PCI, moderate/severe coronary calcification increases the risk of long-term MACE.

摘要

背景

中度/重度冠状动脉钙化(CAC)可预测接受经皮冠状动脉介入治疗(PCI)的患者的临床结局较差。然而,迄今为止,大多数研究规模较小,随访时间有限。我们旨在评估在接受 PCI 的大型队列中钙化严重程度与长期临床结局之间的关系。

方法和结果

共有 10068 例连续接受阜外医院 PCI 的患者纳入本前瞻性观察研究。根据冠状动脉造影的靶病变严重程度的目测,患者分为无/轻度或中度/重度 CAC。评估 5 年时的主要不良心血管事件(MACE),即死亡、心肌梗死和血运重建的复合事件。8229 例(81.7%)患者无/轻度 CAC,1839 例(18.3%)患者中度/重度 CAC。中度/重度 CAC 患者 5 年未计划血运重建的发生率(15.2% vs. 13.2%,P=0.022)和 MACE 发生率(20.7% vs. 17.9%,P=0.005)显著更高。经过倾向评分匹配后,中/重度 CAC 组 5 年未计划血运重建的发生率仍较高(15.2% vs. 12.6%,P=0.019)。使用临床显著变量的 Cox 回归分析显示,中度/重度钙化与 2 年未计划靶血管血运重建的风险增加独立相关(危险比(HR)=1.287,95%置信区间(CI):1.036-1.600,P=0.023)和 MACE(HR=1.242,95% CI:1.039-1.484,P=0.017),但与 5 年未计划血运重建和 MACE 无关。

结论

在接受 PCI 的患者中,中度/重度冠状动脉钙化增加了长期发生 MACE 的风险。

相似文献

1
Long-Term Prognosis of Moderate to Severe Coronary Artery Calcification in Patients Undergoing Percutaneous Coronary Intervention.经皮冠状动脉介入治疗患者中中重度冠状动脉钙化的长期预后。
Circ J. 2020 Dec 25;85(1):50-58. doi: 10.1253/circj.CJ-20-0761. Epub 2020 Dec 9.
2
[Impact of coronary artery lesion calcification on the long-term outcome of patients with coronary heart disease after percutaneous coronary intervention].冠状动脉病变钙化对冠心病患者经皮冠状动脉介入治疗后长期预后的影响
Zhonghua Xin Xue Guan Bing Za Zhi. 2019 Jan 24;47(1):34-41. doi: 10.3760/cma.j.issn.0253-3758.2019.01.004.
3
Prevalence, predictors, prognostic significance, and effect of techniques on outcomes of coronary lesion calcification following implantation of drug-eluting stents: a patient-level pooled analysis of stent-specific, multicenter, prospective IRIS-DES registries.药物洗脱支架置入术后冠状动脉病变钙化的流行率、预测因素、预后意义及技术对结局的影响:支架特异性、多中心、前瞻性 IRIS-DES 注册研究的患者水平汇总分析。
Coron Artery Dis. 2021 Jan;32(1):42-50. doi: 10.1097/MCA.0000000000000896.
4
Combined and independent impact of coronary artery calcification and inflammation on risk for adverse cardiovascular events after percutaneous coronary intervention: Results from a large single-center registry.经皮冠状动脉介入治疗后冠状动脉钙化和炎症对不良心血管事件风险的联合及独立影响:来自大型单中心注册研究的结果
Catheter Cardiovasc Interv. 2020 Sep 1;96(3):E278-E286. doi: 10.1002/ccd.28784. Epub 2020 Feb 22.
5
Coronary Calcification and Long-Term Outcomes According to Drug-Eluting Stent Generation.冠状动脉钙化与药物洗脱支架世代与长期预后。
JACC Cardiovasc Interv. 2020 Jun 22;13(12):1417-1428. doi: 10.1016/j.jcin.2020.03.053.
6
Prevalence, correlates, and impact of coronary calcification on adverse events following PCI with newer-generation DES: Findings from a large multiethnic registry.新一代药物洗脱支架PCI术后冠状动脉钙化的患病率、相关因素及其对不良事件的影响:一项大型多民族注册研究的结果
Catheter Cardiovasc Interv. 2018 Apr 1;91(5):859-866. doi: 10.1002/ccd.27204. Epub 2017 Jul 19.
7
One-Year Outcomes After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction With Varying Quantities of Coronary Artery Calcium (from a 13-Year Registry).ST段抬高型心肌梗死患者经皮冠状动脉介入治疗后1年结局:冠状动脉钙化量不同时的情况(来自一项13年的登记研究)
Am J Cardiol. 2016 Oct 15;118(8):1111-1116. doi: 10.1016/j.amjcard.2016.07.022. Epub 2016 Jul 28.
8
Ischemic outcomes after coronary intervention of calcified vessels in acute coronary syndromes. Pooled analysis from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) and ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) TRIALS.急性冠状动脉综合征中钙化病变血管经皮冠状动脉介入治疗后的缺血结局。HORIZONS-AMI(急性心肌梗死中血管重建和支架与优化药物治疗的比较)和 ACUITY(急性冠状动脉介入治疗即刻危险分层及早期介入策略)试验的汇总分析。
J Am Coll Cardiol. 2014 May 13;63(18):1845-54. doi: 10.1016/j.jacc.2014.01.034. Epub 2014 Feb 19.
9
Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration.经皮冠状动脉介入治疗(PCI)联合药物洗脱支架(DES)治疗女性患者中冠状动脉钙化的相关性及其影响:来自女性创新和药物洗脱支架(WIN-DES)合作研究。
JACC Cardiovasc Interv. 2016 Sep 26;9(18):1890-901. doi: 10.1016/j.jcin.2016.06.022.
10
Angiographic Coronary Calcification: A Simple Predictor of Long-Term Clinical Outcomes in Patients with Acute Myocardial Infarction.冠状动脉钙化的血管造影表现:急性心肌梗死患者长期临床结局的简单预测因子。
J Atheroscler Thromb. 2023 Aug 1;30(8):990-1001. doi: 10.5551/jat.63856. Epub 2022 Oct 22.

引用本文的文献

1
Characterization of Coronary Artery Disease in Sepsis Survivors.脓毒症幸存者冠状动脉疾病的特征
Biomedicines. 2025 May 13;13(5):1181. doi: 10.3390/biomedicines13051181.
2
Overview of Therapeutic Ultrasound Applications and Safety Considerations: 2024 Update.治疗性超声应用概述与安全考量:2024年更新
J Ultrasound Med. 2025 Mar;44(3):381-433. doi: 10.1002/jum.16611. Epub 2024 Nov 11.
3
Machine learning-based coronary artery calcium score predicted from clinical variables as a prognostic indicator in patients referred for invasive coronary angiography.
基于机器学习的冠状动脉钙评分可从临床变量预测,在接受有创冠状动脉造影的患者中作为预后指标。
Eur Radiol. 2024 Sep;34(9):5633-5643. doi: 10.1007/s00330-024-10629-3. Epub 2024 Feb 10.
4
Association of NPC1L1 and HMGCR gene polymorphisms with coronary artery calcification in patients with premature triple-vessel coronary disease.NPC1L1 和 HMGCR 基因多态性与早发三血管病变患者冠状动脉钙化的关系。
BMC Med Genomics. 2024 Jan 17;17(1):22. doi: 10.1186/s12920-024-01802-0.
5
Triglyceride to High-Density Lipoprotein Ratio can predict coronary artery calcification.甘油三酯与高密度脂蛋白比值可预测冠状动脉钙化。
Pak J Med Sci. 2022 Mar-Apr;38(3Part-I):624-631. doi: 10.12669/pjms.38.3.5290.
6
3-Year outcomes in patients with heavily calcified lesions undergoing percutaneous coronary intervention using cutting balloons.使用切割球囊行经皮冠状动脉介入治疗严重钙化病变患者的 3 年结果。
BMC Cardiovasc Disord. 2022 Apr 21;22(1):187. doi: 10.1186/s12872-022-02622-9.
7
Bibliometric and Visual Analysis of Vascular Calcification Research.血管钙化研究的文献计量学与可视化分析
Front Pharmacol. 2021 Jul 15;12:690392. doi: 10.3389/fphar.2021.690392. eCollection 2021.